Papakostas Y, Markianos M, Papadimitriou G, Stefanis N, Lykouras L, Stefanis C
Athens University Medical School, Eginition Hospital, Greece.
Eur Neuropsychopharmacol. 1993 Mar;3(1):75-9. doi: 10.1016/0924-977x(93)90297-y.
The effect of pindolol, a beta-receptor blocker with potent 5-HT1 receptor antagonistic properties, on the prolactin (PRL) and thyrotropin (TSH) responses to electroconvulsive therapy (ECT) was systematically studied in 12 female depressed patients. In a balanced order, crossover design, the patients were given placebo or pindolol 5 mg orally, 1 h prior to bilateral ECT. The last five patients were additionally tested with 10 mg pindolol during the third ECT. Plasma levels of PRL and TSH increased in all three trials, but no consistent effect of pindolol on these hormonal responses could be demonstrated. Pindolol tended to attenuate seizure duration, especially at the 10 mg dose. The participation of 5-HT1 receptor activity in the secretion of PRL and TSH during ECT remains uncertain.
在12名女性抑郁症患者中，系统研究了具有强效5-羟色胺1（5-HT1）受体拮抗特性的β受体阻滞剂吲哚洛尔对电惊厥治疗（ECT）所致催乳素（PRL）和促甲状腺激素（TSH）反应的影响。在平衡顺序的交叉设计中，患者在双侧ECT前1小时口服安慰剂或5毫克吲哚洛尔。最后5名患者在第三次ECT期间额外接受了10毫克吲哚洛尔的测试。在所有三项试验中，PRL和TSH的血浆水平均升高，但未证明吲哚洛尔对这些激素反应有一致影响。吲哚洛尔倾向于缩短癫痫发作持续时间，尤其是在10毫克剂量时。5-HT1受体活性在ECT期间PRL和TSH分泌中的作用仍不确定。
